CUTISS secures CHF 25 million in Series C Funding and advances to Phase 3 clinical trials

Leading Biotech startup CUTISS, at the forefront of skin regenerative medicine and tissue engineering, has announced the successful first closing of CHF 25 million in its Series C funding round. This milestone brings the total raised to CHF 92 million, supporting its efforts as it enters Phase 3 clinical trials.

CUTISS develops innovative, personalized, and automated skin tissue therapy for severe skin injuries. The fresh funding round allows the UZH spin-off to enter Phase 3 clinical trials for its skin therapy, denovoSkin, following long-term safety and improved scar quality in severe burn patients, during Phase 2. The funds will also advance the automation of denovoSkin bioengineering and prepare for the launch of VitiCell, a Vitiligo treatment device.

The Series C round is co-led by Giammaria Giuliani’s family office and a new US family investor represented by Shiloh Advisors AG, with an invitation for new investors to join.

CUTISS was ranked among the TOP 100 Scale-ups in 2023 and the TOP 100 Swiss Startups from 2017 to 2022, and participated in Venture Leaders Life Sciences in 2018. "Venture Leaders in Boston has been a fantastic experience and a true door opener to numerous business development opportunities. I made many excellent contacts with Biotech professionals who helped shape our future development," stated Daniela Marino, Co-Founder and CEO of CUTISS.


CUTISS' team